Loading...
•
Sep 30, 2020
PDS Biotechnology Q3 2020 Earnings Report
PDS Biotechnology reported financial results for the third quarter of 2020 and provided a business update.
Key Takeaways
PDS Biotechnology reported a net loss of $3.9 million, or $0.23 per share, for the third quarter of 2020. The company's cash balance was $33.5 million as of September 30, 2020.
Raised approximately $19 million via a public offering of common stock.
Initiated VERSATILE-002, a Phase 2 trial of PDS0101 in combination with KEYTRUDA® for first-line treatment of patients with metastatic or recurrent HPV-positive head and neck cancer.
Initiated a Phase 2 study of PDS0101 in combination with standard of care chemoradiotherapy at the MD Anderson Cancer Center for treatment of locally advanced cervical cancer.
Advanced co-development program with Farmacore with plans to move the PDS0203 COVID-19 vaccine into clinical development with the support of the Brazilian government.
Forward Guidance
PDS Biotech is focused on progressing the clinical development of its oncology programs and expanding its oncology and infectious disease programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...